文献速递乳腺癌放疗

腋窝外侧胸血管交界区剂量约束与乳腺癌相关淋巴水肿风险

Identifying the Axillary Substructure at Risk for Lymphedema in Operable Patients With Breast Cancer Receiving Regional Nodal Irradiation.
PubMed 文献 · Pract Radiat Oncol · 2026-01-13

中位随访60个月,BCRL累积发生率为33.9%,最显著的剂量学参数为腋窝外侧胸血管交界区(ALTJ)-V35Gy≥79.2%。结论提示ALTJ-V35Gy<79.2%可作为推荐剂量约束,避免ALTJ过度照射在临床上可行且安全。

要点

  • 中位随访60个月,患者报告的BCRL累积发生率为33.9%。
  • ALTJ-V35Gy≥79.2%是与BCRL最显著的剂量学参数。
  • ALTJ-V35Gy<79.2%可作为ALND后RNI患者的推荐剂量约束。

核心结论

  • ALTJ-V35Gy<79.2%可能作为腋窝淋巴结清扫后接受区域淋巴结照射患者的推荐剂量约束。
  • 避免ALTJ过度照射在临床上可行且安全,可能在不影响高危淋巴结区域覆盖的前提下降低BCRL风险。

研究设计与样本

  • Cohort-Initial纳入2018年8月至2021年2月间336例pT1-3N0-1M0乳腺癌患者,均接受乳房切除或保乳手术联合腋窝淋巴结清扫及区域淋巴结照射。
  • Cohort-Recurrence包含50例经PET/CT诊断区域淋巴结复发的连续ALND治疗患者,用于评估候选亚结构的复发风险。
  • Cohort-Reoptimization包含20例来自Cohort-Initial且候选亚结构接受过高辐射剂量的患者,重新优化治疗计划以评估降低剂量的可行性。

主要发现

  • 患者报告的BCRL累积发生率为33.9%,中位随访60个月。
  • 显著基线风险因素包括BMI≥27.18 kg/m2、肿瘤大小≥1.9 cm、绝经前状态和≥18枚淋巴结切除(均P<.05)。
  • 最显著的剂量学参数为ALTJ-V35Gy≥79.2%。
  • 结合临床病理因素和ALTJ参数的预测列线图具有合理准确性,自训练AUC为0.780,内部验证AUC为0.769。
  • Cohort-Recurrence中196枚FDG高摄取区域淋巴结均未位于ALTJ内。

关键数值与推荐

  • ALTJ-V35Gy<79.2%为推荐剂量约束。
  • 基线风险因素阈值:BMI≥27.18 kg/m2、肿瘤大小≥1.9 cm、绝经前状态、≥18枚淋巴结切除(均P<.05)。
  • 预测列线图AUC:自训练0.780,内部验证0.769。

临床怎么用

  • 对接受ALND和RNI的可手术乳腺癌患者,可考虑将ALTJ-V35Gy<79.2%作为剂量约束以降低BCRL风险。
  • 结合BMI、肿瘤大小、绝经状态和淋巴结切除数等基线因素识别BCRL高危患者。
  • 避免ALTJ过度照射在临床上可行,且不影响靶区覆盖和器官剂量。

局限性

  • BCRL采用患者报告的Norman问卷评估,可能存在主观偏倚。
  • Cohort-Reoptimization样本量较小(20例),需进一步验证。
  • 预测列线图仅进行内部验证,缺乏外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Axillary substructures may contribute to the development of breast cancer-related lymphedema (BCRL). This study aimed to compare dose-volume parameters of various substructures to identify high-risk regions associated with BCRL and to evaluate the clinical applicability of these findings. METHODS AND MATERIALS: Cohort-Initial included 336 patients with pT1-3N0-1M0 breast cancer who underwent mastectomy or lumpectomy with axillary lymph node dissection (ALND) and regional nodal irradiation (RNI) between August 2018 and February 2021. The Norman questionnaire was used to assess BCRL. Thirteen dose-volume parameters across 8 axillary substructures were assessed for association with BCRL. Cohort-Recurrence comprised 50 consecutive ALND-treated patients with regional nodal recurrence diagnosed using positron emission tomography/computed tomography, used to evaluate the recurrence risk in the candidate substructures. Cohort-Reoptimization involved 20 patients from the Cohort-Initial who received excessive radiation doses in the candidate substructure. Their treatment plans were reoptimized to assess the feasibility of dose reduction while maintaining target coverage and organ dose. RESULTS: The patient-reported cumulative incidence of BCRL was 33.9% during a median follow-up of 60 months. Significant baseline risk factors included body mass index ≥ 27.18 kg/m2, tumor size ≥ 1.9 cm, premenopausal status, and ≥ 18 lymph nodes removed (all P < .05). The most significant dosimetric parameter was axillary-lateral thoracic vessel juncture (ALTJ)-V35Gy ≥ 79.2%. A predictive nomogram incorporating these clinicopathologic factors and the ALTJ parameter was developed with reasonable accuracy, as confirmed by self-training (area under the curve value, 0.780) and internal validation (area under the curve value, 0.769). None of the 196 fluorodeoxyglucose-avid regional nodes in Cohort-Recurrence were located within the ALTJ. Reoptimization of ALTJ-V35Gy was feasible without compromising the radiation therapy plan quality. CONCLUSIONS: ALTJ-V35Gy < 79.2% may serve as a recommended dose constraint for patients undergoing RNI after ALND. Avoiding excessive radiation to the ALTJ is clinically feasible and safe, potentially mitigating BCRL risk without compromising dose coverage to high-risk nodal regions.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Huang JQ, Zheng SY, Zhang MC, et al. Identifying the Axillary Substructure at Risk for Lymphedema in Operable Patients With Breast Cancer Receiving Regional Nodal Irradiation. Pract Radiat Oncol. 2026. PMID: 41528285. doi:10.1016/j.prro.2025.12.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。